

AmCham Greece  
HealthWorld Conference 2022

# Pharma innovation in Greece: Opportunities and challenges

October 5<sup>th</sup>, 2022

Remo Gujer  
General Manager, CEETII Cluster

 Bristol Myers Squibb™



# The Bristol Myers Squibb footprint in the world



**\$11.1** bil.  
investment in R&D  
in 2020



**50+**  
countries where we  
have a presence



**30,000+**  
employees



**50+**  
molecules in clinical  
research - Possibility  
of transition to full  
development in the  
next three years



**41**  
disease areas  
being studied



**\$150** mil.  
through the  
Bristol Myers Squibb  
Foundation to address  
health inequalities  
worldwide

# Pharma innovation as a driver of better health, social and financial outcomes

21%

lower mortality rate in all cancers in Europe in the last 30 years<sup>1</sup>

37%

lower mortality rate in cardiovascular diseases in Europe between 2000 -2015<sup>2</sup>

1.74  
years

increase in life expectancy in Europe between 2005-2015 - Innovative medicines contributed by 73%<sup>3</sup>

0.9  
years

increase in life expectancy in Greece thanks to pharma innovation between 1995 and 2015<sup>4</sup>

100  
mil.

annual investment in clinical research by pharma companies in Greece - Prospects for an increase to EUR 500 million up to 2027<sup>5</sup>

1. Health Advances analysis; WHO Mortality Database

2. PhRMA 2016 Prescription Medicines: Costs in Context


3. EFPIA, The pharmaceutical industry in Figures, Key Data, 2017

4. Department of Health Economics, National School of Public Health, Management, control and evaluation of pharmaceutical innovation in Greece, Kastaniotis Publications, 2016

5. EFPIA, The pharmaceutical industry in Figures, Key Data, 2017

# Greece ensures comparatively early access to innovative medicines - **The oncology case**

Within Europe, huge inequalities exist in time to Market Access and Patient Access to new oncology therapies



**Greece**




Greece has a better performance in terms of early access to innovative medicines in oncology in comparison to other European countries.





Access granted at EC decision through interim reimbursement options.

# Pharmaceutical expenditure is increasing; however, the public budget remains stable and insufficient - Hospital environment




Source: IOBE-SFEE, The Pharmaceutical Market in Greece, Facts and Figures, 2021

# Recent legislative developments disproportionately pass on the overrun burden to companies with innovative portfolio



As a result, companies like Bristol Myers Squibb delivering 1) innovative medicines 2) in hospital environment bear the brunt of the insufficient public budget.

# Towards a sustainable future of access to innovation



Predictability



New financial resources



Optimized allocation through structural reforms - Broader generic penetration



Abolishment of clawback - rationalization of mandatory payments



R&D investment incentives



AmCham Greece  
HealthWorld Conference 2022

# Pharma innovation in Greece: Opportunities and challenges

October 5<sup>th</sup>, 2022

Remo Gujer  
General Manager, CEETII Cluster

 Bristol Myers Squibb™

